- Home
- RS vs RPRX Comparison
RS vs RPRX Comparison
Compare RS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RS
- RPRX
- Stock Information
- Founded
- RS 1939
- RPRX 1996
- Country
- RS United States
- RPRX United States
- Employees
- RS N/A
- RPRX N/A
- Industry
- RS Metal Fabrications
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- RS Industrials
- RPRX Health Care
- Exchange
- RS Nasdaq
- RPRX Nasdaq
- Market Cap
- RS 14.5B
- RPRX 16.2B
- IPO Year
- RS 1994
- RPRX 2020
- Fundamental
- Price
- RS $270.51
- RPRX $39.23
- Analyst Decision
- RS Buy
- RPRX Strong Buy
- Analyst Count
- RS 5
- RPRX 3
- Target Price
- RS $323.00
- RPRX $46.00
- AVG Volume (30 Days)
- RS 365.9K
- RPRX 3.9M
- Earning Date
- RS 10-22-2025
- RPRX 11-05-2025
- Dividend Yield
- RS 1.78%
- RPRX 2.25%
- EPS Growth
- RS N/A
- RPRX N/A
- EPS
- RS 13.63
- RPRX 1.75
- Revenue
- RS $13,922,300,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- RS $5.79
- RPRX $36.16
- Revenue Next Year
- RS $4.17
- RPRX $2.04
- P/E Ratio
- RS $19.82
- RPRX $22.36
- Revenue Growth
- RS N/A
- RPRX 3.70
- 52 Week Low
- RS $250.07
- RPRX $24.05
- 52 Week High
- RS $347.44
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- RS 41.54
- RPRX 59.26
- Support Level
- RS $269.34
- RPRX $38.39
- Resistance Level
- RS $277.99
- RPRX $40.01
- Average True Range (ATR)
- RS 6.18
- RPRX 1.26
- MACD
- RS -0.28
- RPRX 0.12
- Stochastic Oscillator
- RS 11.88
- RPRX 63.19
About RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.